IP Library Granted Patent US 9,757,497
Granted Patent B2
US 9,757,497 · App. 13/469,844 · Granted Sep 12, 2017

Delivery of coated hydrophobic active agent particles

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,757,497
App. No.
13/469,844
Granted
Sep 12, 2017
Kind
B2
Abstract

Embodiments of the invention include devices and coatings for devices including coated hydrophobic active agent particles. In an embodiment, the invention includes a drug delivery device including a substrate; and coated therapeutic agent particles disposed on the substrate, the coated therapeutic agent particles comprising a particulate hydrophobic therapeutic agent; and a cationic agent in contact with the particulate hydrophobic therapeutic agent. Other embodiments are also included herein.

Claims (13)

1. A drug delivery coating comprising

a polymeric layer, the polymeric layer comprising a hydrophilic outer surface;

coated therapeutic agent particles disposed over the hydrophilic outer surface, the coated therapeutic agent particles comprising

a particulate hydrophobic therapeutic agent core;

and a cationic agent selected from the group consisting of polyethyleneimine (PEI), 1,2-dioleoyl-3-trimethylammonium-propone (DOTAP) and polyamidoamine dendrimers (PAMAM) in contact with the particulate hydrophobic therapeutic agent core;

further comprising the cationic agent disposed between the coated therapeutic agent particles;

wherein the coated therapeutic agent particles and cationic agent directly contact an in vivo environment when the drug delivery coating is disposed within a vessel of a subject.

2. The drug delivery coating of claim 1 , further comprising an additive disposed between the coated therapeutic agent particles, the additive selected from the group consisting of saccharides and amphiphilic compounds.

3. The drug delivery coating of claim 2 , the additive selected from the group consisting of glycogen, dextran, and F68 poloxamer.

4. The drug delivery coating of claim 1 , further comprising an additive disposed between the coated therapeutic agent particles, the additive selected from the group consisting of polyethylene glycol and derivative thereof, polyvinyl pyrrolidone and derivatives thereof, polyvinyl alcohol and derivatives thereof, and poloxamers.

5. The drug delivery coating of claim 1 , wherein the particulate hydrophobic therapeutic agent is in a crystalline form.

6. The drug delivery coating of claim 1 , the particulate hydrophobic therapeutic agent selected from the group consisting of paclitaxel and sirolimus.

7. The drug delivery coating of claim 1 , the polymeric layer comprising polyvinylpyrrolidone.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2025
From: SURMODICS, INC.
To: SURMODICS MD, LLC
Reel/Frame 073894/0058 →
RELEASE OF SECURITY INTEREST Recorded Nov 24, 2025
From: MIDCAP FUNDING IV TRUST
To: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
Reel/Frame 073690/0186 →
SECURITY INTEREST Recorded Aug 23, 2024
From: SURMODICS, INC.; SURMODICS SHARED SERVICES, LLC; SURMODICS HOLDINGS, LLC; SURMODICS COATINGS, LLC; SURMODICS MD, LLC; SURMODICS COATINGS MFG, LLC; SURMODICS IVD, INC.; SURMODICS MD OPERATIONS, LLC; NORMEDIX, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 068762/0423 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 14, 2012
From: SLAGER, JORAM
To: SURMODICS, INC.
Reel/Frame 028374/0858 →